NCT05038826 is a clinical trial in Lung Cancer, sponsored by Median Technologies.

Who is sponsoring NCT05038826?

NCT05038826 is sponsored by Median Technologies.

What condition does NCT05038826 study?

NCT05038826 studies Lung Cancer.

Is NCT05038826 still recruiting?

NCT05038826 is currently completed. Last updated 14 March 2023.

Last reviewed 2023-03-14 · How we verify

NCT05038826

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

BICR in New Therapeutic Lung Cancer Trials

Completed Last updated 14 March 2023

What this trial tests

trial in Lung Cancer in 1,833 participants. Completed in 1 December 2021.

Timeline

1 February 2021

Primary endpoint
10 August 2021

1 December 2021

Quick facts

Lead sponsor	Median Technologies
Status	Completed
Study type	OBSERVATIONAL
Enrollment	1,833
Start date	1 February 2021
Primary completion	10 August 2021
Estimated completion	1 December 2021
Sites	1 location across France

Conditions studied

Lung Cancer — all drugs for Lung Cancer →

Sponsor

Median Technologies

Who can join

Eligibility, any sex, with Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Double reads in blinded independent central reviews (BICRs) are recommended to control the quality of trials but they are prone to discordances. We analyzed inter-reader discordances in a pool of lung cancer trials using RECIST 1.1.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Blinded Independent Central Review (BICR) in New Therapeutic Lung Cancer Trials.
Beaumont H, Iannessi A, Wang Y, Voyton CM, et al · · 2021 · cited 9× · PMID 34572761 · DOI 10.3390/cancers13184533

Verify or expand the search:

Other recruiting trials for Lung Cancer

Currently open trials in the same condition.

NCT07295821 — Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study · Phase 2 · recruiting
NCT06909201 — Hyperpolarized Xenon-129 Magnetic Resonance Imaging in Lung Cancer Patients Receiving Radiation Therapy for Investigatin · Phase 1 · recruiting
NCT07524114 — Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception · recruiting
NCT07487064 — Galvanize Aliya® EX Pulsed Electric Field (PEF) Treat and Resect Study · NA · recruiting
NCT07146568 — Evaluating the Implementation and Effectiveness of the Pink and Pearl Campaign on Lung Cancer Screening at Christian Hos · NA · recruiting

Other Median Technologies trials

Trials by the same sponsor.

NCT06751576 — Retrospective Clinical Trial Comparing Radiologists' Diagnosis Accuracy in Lung Cancer Screening Population With and Wit · completed
NCT06576232 — Standalone Observational Study Assessing the Performance of an AI/ML Tech-based SaMD on Chest LDCT Images (REALITY) · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05038826 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Median Technologies
Last refreshed: 14 March 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05038826.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing